Abstract: The invention relates to parathyroid hormone (PTH) variants and pharmaceutical compositions comprising same. The invention further relates to PTH compositions with improved serum half-life and peak-trough ratios, and methods of controlling serum calcium levels with the PTH variants and compositions of the invention. The invention further relates to methods of treating hypoparathyroidism and/or hypocalcemia due to hypoparathyroidism with the PTH variants and compositions of the invention.
Type:
Grant
Filed:
January 29, 2020
Date of Patent:
April 25, 2023
Assignee:
SHIRE-NPS PHARMACEUTICALS, INC.
Inventors:
Clark Pan, Angela Norton, Kevin Holmes, David Bruce Lloyd, Bryan James Goodwin, Rongxin Shi, Sujit Jain, Chuan Shen
Abstract: Described are fusion proteins of GLP-2 with an Fc region of immunoglobulin. The GLP-2 and Fc regions are separated by a linker comprised of amino acids. The fusion proteins persist and remain active in the body for longer periods of time than GLP-2 itself. Methods are disclosed of using the fusion proteins to treat and prevent enterocutaneous fistulae, radiation damage to the gastrointestinal tract, obstructive jaundice, and short bowel syndrome.
Type:
Application
Filed:
April 15, 2022
Publication date:
February 2, 2023
Applicant:
SHIRE-NPS PHARMACEUTICALS, INC.
Inventors:
Clark Pan, Angela Norton, Bettina Strack-Logue
Abstract: Described are fusion proteins of GLP-2 with an Fc region of immunoglobulin. The GLP-2 and Fc regions are separated by a linker comprised of amino acids. Methods are disclosed of using the fusion proteins to treat and prevent enterocutaneous fistulae, radiation damage to the gastrointestinal tract, obstructive jaundice, and short bowel syndrome.
Abstract: The invention relates to pharmaceutical compositions and dosage forms comprising full-length recombinant human parathyroid hormone (rhPTH(1-84)). The invention further relates to new and/or improved PTH compositions having improved in-use stability that are resistant to protein degradation in response to physical and chemical stresses.
Type:
Application
Filed:
July 12, 2019
Publication date:
October 14, 2021
Applicant:
SHIRE-NPS PHARMACEUTICALS, INC.
Inventors:
Nitin DIXIT, Vinh NGUYEN, Pierre SOUILLAC, Sujii BASU
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Application
Filed:
April 7, 2021
Publication date:
August 5, 2021
Applicant:
SHIRE-NPS PHARMACEUTICALS, INC.
Inventors:
Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Application
Filed:
March 26, 2021
Publication date:
July 15, 2021
Applicant:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Application
Filed:
March 29, 2021
Publication date:
July 15, 2021
Applicant:
SHIRE-NPS PHARMACEUTICALS, INC.
Inventors:
Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Application
Filed:
March 19, 2021
Publication date:
July 8, 2021
Applicant:
Shire-NPS Pharmaceuticals, Inc,
Inventors:
Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer Lopansri, Consuelo M. Blosch
Abstract: GLP-2 analogs, such as teduglutide, and fusion proteins of GLP-2 with immunoglobulin are administered before, during or after surgery, particularly resection of the small intestine. When short bowel syndrome develops after surgical resection of the small intestine, parenteral nutrition is usually necessary to compensate for reduced absorption of water and nutrients across the small intestine. GLP-2 analogs and GLP-2 fusion proteins promote growth of small intestine, improve nutrient absorption and can reduce the need for parenteral nutrition after surgery.
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Application
Filed:
November 20, 2020
Publication date:
March 18, 2021
Applicant:
SHIRE-NPS PHARMACEUTICALS, INC.
Inventors:
Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Application
Filed:
October 27, 2020
Publication date:
February 11, 2021
Applicant:
SHIRE-NPS PHARMACEUTICALS, INC.
Inventors:
Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Application
Filed:
October 5, 2020
Publication date:
January 21, 2021
Applicant:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Application
Filed:
October 5, 2020
Publication date:
January 21, 2021
Applicant:
SHIRE-NPS PHARMACEUTICALS, INC.
Inventors:
Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Application
Filed:
September 18, 2020
Publication date:
January 7, 2021
Applicant:
SHIRE-NPS Pharmaceuticals, INC.
Inventors:
Elizabeth L. SANGUINETTI, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Application
Filed:
September 3, 2020
Publication date:
December 31, 2020
Applicant:
SHIRE-NPS PHARMACEUTICALS, INC
Inventors:
Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Application
Filed:
September 2, 2020
Publication date:
December 24, 2020
Applicant:
SHIRE-NPS PHARMACEUTICALS, INC.
Inventors:
Elizabeth L. SANGUINETTI, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Application
Filed:
August 28, 2020
Publication date:
December 17, 2020
Applicant:
SHIRE-NPS PHARMACEUTICALS, INC.
Inventors:
Elizabeth L. SANGUINETTI, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Application
Filed:
August 21, 2020
Publication date:
December 3, 2020
Applicant:
SHIRE-NPS PHARMACEUTICALS, INC.
Inventors:
Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Application
Filed:
August 21, 2020
Publication date:
December 3, 2020
Applicant:
SHIRE-NPS PHARMACEUTICALS, INC.
Inventors:
Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Application
Filed:
August 13, 2020
Publication date:
November 26, 2020
Applicant:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH